Combined Molecular Biology Test is the First to Distinguish Benign Pancreatic Lesions

LW Newsfeed

When performed in tandem, two molecular biology laboratory tests distinguish, with near certainty, pancreatic lesions that mimic early signs of cancer but are completely benign. The lesions almost never progress to cancer, so patients may be spared unnecessary pancreatic cancer screenings or operations.
The two-test combination is the only one to date that can accurately and specifically identify these benign pancreatic lesions. Its utility was described in one of the largest studies of patients with this form of pancreatic lesion by researchers from Indiana University, Indianapolis. The results of the study now appear in an “article in press” on the Journal of the American College of Surgeons website in advance of print publication. Read more . . .
image_printPrint Page

Conversation